Verastem, Inc. (NASDAQ: VSTM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates [Yahoo! Finance]
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Verastem Oncology submits NDA for ovarian cancer treatment [Yahoo! Finance]
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer